FRNM Healthcare

Freenome, Inc.

$11.47-1.21%

Price as of close on Nov 3, 2026 · Financials updated Nov 4, 2026

Basics

Sector: Healthcare
Industry: Diagnostics & Research
Country: United States
Market cap: 1.2B USD
Enterprise value: 2.8B USD
Full-time employees: 375

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: less short-term liquidity (current ratio 0.20 vs a peer median of 2.59)higher risk: less liquidity (current ratio 0.20 vs peers 2.59)
Not enough data: growth

Would rank #1,156 of 1,157 fully scored healthcare companies (bottom 1%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Freenome's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.
Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -735%).

StockQuotient Score

3/ 100

Oct 5 3 → Nov 4 3

Valuation

Is the price right?

0/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-0.1%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-7.3%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yieldUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-0.5%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

3/100

Weak

2/3 inputs reported · Partial data

Since last quarter: ▼ Weaker

Turned to a loss over the last 12 months

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-734.9%

Yahoo Finance fallback · SEC operating income not reported in standard form · fiscal year to Dec 2025Reported value33% base weight · Z-score -60.95Sector median: 0.0706 · MAD: 0.1217

Return on assets-0.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.48Sector median: 0.0166 · MAD: 0.0537

Return on invested capitalUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equityUnavailable

Missing · left out of the scoreInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 7 → 6

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Weaker than most peers on:

▼ Current ratio
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.60

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.09Sector median: 0.6250 · MAD: 0.3380

Current ratio0.20×

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentile33% base weight · Z-score -1.29Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Freenome

Is Freenome getting weaker?: Its latest SEC filing (Aug 18, 2026) got weaker in some ways: turned to a loss over the last 12 months. Its overall score is unchanged at 3/100 since Oct 28, 2026.
How is Freenome valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -0.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.1% vs peers 1.5% (weaker than 100% of peers).
Is Freenome growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Freenome?: Less profitable than most of its peers. Profitability scores 3/100 against 1,393 healthcare peers. Operating margin -734.9% vs a peer median of 7.1% (weaker than 94% of peers).Operating margin -734.9% vs peers 7.1% (weaker than 94% of peers).
How risky is Freenome?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 0.20× vs a peer median of 2.59× (weaker than 100% of peers).Current ratio 0.20× vs peers 2.59× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 18, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Turned to a loss over the last 12 months

Worth watching: Freenome is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Net income (12 months)	107,164 USD	−762,626 USD	turned negative
Cash	567,179 USD	437,369 USD	−22.9%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Diagnostics & Research · 26 companies

Valuations in Diagnostics & Research are within their usual range since Nov 2018.

53% of months since Nov 2018 were valued lower than now.
24% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +109% vs the whole market, against a usual +111%.

Nov 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2025	Change
Return on assets (ROA)	0.9%	—
Current ratio	0.40×	—

FRNM price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: less short-term liquidity (current ratio 0.20 vs a peer median of 2.59)higher risk: less liquidity (current ratio 0.20 vs peers 2.59)

Not enough data: growth

Would rank #1,156 of 1,157 fully scored healthcare companies (bottom 1%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Freenome's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.

Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -735%).

Questions investors ask about Freenome

Is Freenome getting weaker?

Its latest SEC filing (Aug 18, 2026) got weaker in some ways: turned to a loss over the last 12 months. Its overall score is unchanged at 3/100 since Oct 28, 2026.

How is Freenome valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 0/100 against 1,393 healthcare peers. Earnings yield -0.1% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -0.1% vs peers 1.5% (weaker than 100% of peers).

Is Freenome growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Freenome?

Less profitable than most of its peers. Profitability scores 3/100 against 1,393 healthcare peers. Operating margin -734.9% vs a peer median of 7.1% (weaker than 94% of peers).Operating margin -734.9% vs peers 7.1% (weaker than 94% of peers).

How risky is Freenome?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 0.20× vs a peer median of 2.59× (weaker than 100% of peers).Current ratio 0.20× vs peers 2.59× (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

107,164 USD

−762,626 USD

turned negative

Cash

567,179 USD

437,369 USD

−22.9%

Key ratios

FY 2025

Change

Return on assets (ROA)

0.9%

—

Current ratio

0.40×

—